Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

Prof Patrick Forde of the Trinity St James’s Cancer Institute presented the findings at the latest meeting of the American ...

The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in ...

Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer (NSCLC) - the ...

US FDA accepts Roche’s sBLA and grants priority review status for Tecentriq to treat NSCLC: Basel Wednesday, August 4, 2021, 12:00 Hrs [IST] Roche announced that the US Food and ...

CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease ...